Get started
Author

D. Bryan Johnson

Observed names: D. Brian Johnson, Darrell Johnson
Observed institution: Strata Oncology (United States)
ORCID: 0009-0004-3228-6100
Observed ORCID: 0009-0004-3228-6100
OpenAlex ID: A5007133435
Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples
2021 · Scott A. Tomlins, Daniel H. Hovelson, et al. · JCO Precision Oncology · 37
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
2023 · Scott A. Tomlins, Nickolay A. Khazanov, et al. · Communications Medicine · 31
PDF
Development and Validation of StrataNGS, a Multiplex PCR, Semiconductor Sequencing-Based Comprehensive Genomic Profiling Test
2021 · Scott A. Tomlins, Daniel H. Hovelson, et al. · Journal of Molecular Diagnostics · 24
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al. · Cancer Research Communications · 12
PDF
Genomic and Immune Landscape of Non–Small Cell Lung Cancer Brain Metastases
2025 · Manlu Liu, Justin C. Jagodinsky, et al. · JCO Precision Oncology · 6
Immune and Genomic Heterogeneity of MET-Altered Non–Small Cell Lung Cancer
2025 · Manlu Liu, Rachel L. Minne, et al. · JCO Precision Oncology · 2
Abstract 2171: A multivariate biomarker predicts sacituzumab govitecan response in solid tumors
2023 · Nickolay A. Khazanov, Laura E. Lamb, et al. · Cancer Research · 2
A prospective study of minimal residual disease in urological cancers using circulating tumour DNA
2025 · Arnav Srivastava, Derrian Cooley, et al. · British Journal of Urology · 1
Hepatic adenomas in males: Is molecular characterization helpful in guiding its management?
2025 · Ekta Jain, Sarah A. Anderson, et al. · Human Pathology · 1
Abstract 968: Evaluation of Her2 RNA expression as a potential predictive biomarker for anti-Her2 therapy
2023 · Laura E. Lamb, Nickolay A. Khazanov, et al. · Cancer Research · 1
PP01.106 Validation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab Monotherapy Benefit in First Line (1L) Non-small cell lung cancer (NSCLC)
2024 · Brandi Oakley, Justin Moon, et al. · Journal of Thoracic Oncology
PDF
Abstract PO1-14-04: A multivariate biomarker to guide antibody-drug conjugate selection and provide insight on response differences across breast cancer subtypes
2024 · Laura Lamb, Jonathan Mowers, et al. · Cancer Research
FIGURE 4 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Data S2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Table S7 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
PDF
Supplementary Figure S6 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Data S1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
FIGURE 4 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Table S2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Supplementary Figure S8 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
2023 · Benjamin J. Bulen, Nickolay A. Khazanov, et al.
Works count: 85
Citation count: 117
H-index: 5
I10-index: 4
Year
Topic
Type